Search the Newsreel

Responsive Playbooks and the ETON Inflection

This article provides an AI-driven analysis for Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report suggests …

Harmony Biosciences (NASDAQ:HRMY) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "buy" to a "strong-buy" rating. This upgrade comes as the company reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite this, …

Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu …

Why Eton Pharmaceuticals (ETON) Is Up 32.0% After Q2 Earnings Surge And Raised 2026 Outlook

Eton Pharmaceuticals (ETON) saw its stock rise 32.0% after reporting a significant Q2 2026 earnings turnaround, with revenue surging to US$37.59 million and net income reaching US$11.58 million. The company also raised its full-year 2026 revenue guidance to at least US$145 million and expanded …

(CRMD) as a Liquidity Pulse for Institutional Tactics

Cormedix Inc. (NASDAQ: CRMD) shows a mid-channel oscillation pattern with mixed sentiment across different time horizons. An exceptional short setup is identified with a significant risk-reward ratio. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis …

Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV

This article provides financial data for Rhythm Pharmaceuticals, Inc. (DUS:1RV) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to revenue forward. It notes that the market is closed with no trades recorded at the time of publication. The content is presented …

Marksans Pharma Limited (NSE:MARKSANS) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Is Under Armour (UAA) Undervalued Following Its Guidance Cut?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Under Armour (UAA) is back in focus after updating investors on both near term and full year expectations. The company paired a new …

Permian Basin Royalty Trust (NYSE:PBT) Short Interest Up 106.3% in July

Permian Basin Royalty Trust (NYSE:PBT) experienced a significant increase in short interest, rising 106.3% in July to 288,002 shares. Despite this, institutional investors have been increasing their positions, and the company recently raised its monthly dividend. PBT currently holds a consensus "Hold" rating from …

Permian Resources (PR) On Q2 Earnings And Higher Guidance Looks Cheap But Is It Priced In

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Why Permian Resources stock is back in focus after Q2 earnings Permian Resources (PR) …

Fermi Inc. Earnings Call Shows Big AI Power Bet

Fermi Inc.'s recent Q2 earnings call highlighted significant progress in commercial deals, operational capacity expansion, and improved liquidity, particularly noting a binding agreement with TensorWave for up to 650 MW, expected to generate $6.5 billion in revenue. The company detailed a clear roadmap to …

PFGC Q2 Deep Dive: Convenience and Procurement Initiatives Shape 2026 Results and Outlook

PFGC Q2 Deep Dive: Convenience and Procurement Initiatives Shape 2026 Results and Outlook Food distribution giant Performance Food Group (NYSE:PFGC) missed Wall Street's revenue expectations in Q2 CY2026, but sales rose 6.4% year on year to $18.03 billion. On the other hand, the company's …

FORMUL PLASTIK - KAP Haberleri - 2026-08-15 tarihli

What Is Behind Performance Food Group (PFGC) Stock's Latest Move?

Shanghai Fudan Zhangjiang Bio Pharmaceutical Ltd (SEHK:1349) Stock Profit Rebound Raises Durability Questions

Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Eton Pharmaceuticals (NASDAQ: ETON) saw its shares rise significantly in pre-market trading after reporting stronger-than-expected second-quarter financial results and providing an optimistic revenue guidance for FY26. The company exceeded analyst consensus estimates for both earnings per share and sales. The article also lists other …

Is Teva Pharmaceutical Industries (TEVA) A Bargain On Its TEV 408 Phase 2b Move?

Teva Pharmaceutical Industries (TEVA) has initiated a phase 2b trial for its anti IL-15 antibody TEV-'408 for nonsegmental vitiligo, following promising phase 1b results. This development, coupled with a significant 1-year share price return of 105.88%, has renewed investor interest. While the stock is …

Is BioMarin Pharmaceutical (BMRN) Still Cheap As 2026 Guidance Rises And Amicus Adds Growth?

BioMarin Pharmaceutical (BMRN) has updated its 2026 guidance and completed the Amicus acquisition, leading to increased attention on the stock. Despite strong short-term momentum and a "22% Undervalued" narrative, the article highlights the need for investors to consider inherent risks, such as reliance on …

ETFs Investing in Regeneron Pharmaceuticals, Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that invest in Regeneron Pharmaceuticals, Inc. (RGO) stocks. The list, sorted by market value, details each fund's symbol, market value, weight of RGO stock, issuer, management style, focus, expense ratio, assets under management …

ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold

ANI Pharmaceuticals (ANIP) is currently in focus after reporting its Q2 and H1 2026 results and reaffirming its full-year net revenue outlook of $1,080 million to $1,140 million. Despite recent strong earnings, the stock has seen a short-term decline, though it shows significant long-term …

MTAW/Meta AI Lab Ecosystem ETF - 研究報告與輝達概念股分析 - 股市爆料同學會

This page provides an analysis of the MTAW/Meta AI Lab Ecosystem ETF, including its real-time stock performance, technical and fundamental analysis, and ETF holdings. It shows the current price, trading volume, and intraday highs and lows, noting a slight gain for the ETF. The …

Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals (IONS) has drawn investor attention after recent share price moves, with the stock up over the past month but down over the past …

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at …

What Is Meta Platforms? From Social Media Giant To AI Infrastructure Leader

Can Gorman Rupp (GRC) Justify Its Valuation After Analyst Upgrades?

Gorman-Rupp (GRC) has seen significant share price appreciation and analyst upgrades, with a year-to-date return of 67.86%. While a Simply Wall St DCF model suggests the stock is undervalued at $116.01 compared to its current price of $80.81, its current P/E ratio of 34.2x …

Eton Pharmaceuticals Stock Soars After Huge Q2 Beat And Target Hikes

Eton Pharmaceuticals (ETON) stock surged by 45.78% after reporting a significant Q2 beat, with non-GAAP EPS of $0.43 and revenue of $37.6M, driven by 99% year-over-year growth. The company also raised its 2026 revenue guidance to over $145M and adjusted EBITDA margin to at …

Fermi Has Zero Revenue And A $486M Loss – So Why Is Retail Still Bullish On FRMI Stock?

Eton Pharmaceuticals Soars After Blowout Q2 And Guidance Hike

Eton Pharmaceuticals (NASDAQ: ETON) experienced a significant stock surge of over 45% after reporting blowout Q2 earnings and raising its 2026 revenue guidance. The company's Q2 non-GAAP EPS and revenue significantly beat consensus estimates, driven by strong growth and the successful relaunch of Hemangeol. …

CorMedix Inc (CRMD) Stock News Today

Neo Performance's Record Quarter Sparks a Two-Speed Market Reaction

Will Aurinia’s Reaffirmed 2026 Guidance and Large Buyback Reshape Aurinia Pharmaceuticals' (AUPH) Narrative?

Acumen Pharmaceuticals Inc (ABOS) Stock News Today

Don't Ignore The Insider Selling In Rocket Pharmaceuticals

A Chief Operating Officer at Rocket Pharmaceuticals recently sold US$128k worth of shares, representing 6.8% of their holding. This sale was the largest insider sale in the past year, though it occurred around the current market price, making it less concerning than sales at …

Meta ordered to pay $567M to address harm to New Mexico children

A New Mexico judge has ordered Meta Platforms to pay an additional $567 million to address harm to children in the state, following a jury finding that Meta's social media platforms "substantially contributed to a public nuisance." This ruling comes after an initial $375 …

Lakhbir Lamba Bought 22% More Shares In Regional Management

Lakhbir Lamba, President of Regional Management Corp. (NYSE:RM), recently increased his stake by 22%, purchasing US$316k worth of shares at US$31.65 each. While this is a strong insider buy, overall insider selling exceeded buying over the last year, though the sales were at a …

Sutro Biopharma, Inc. (NASDAQ:STRO) Just Reported And Analysts Have Been Lifting Their Price Targets